Their characteristics are as follows: the median age was 58 years, 93% had ovarian-origin cancer, 87% had a late FIGO (The International Federation of Gynecology and Obstetrics) stage (stage 3 or 4), 77% had grade 3 tumor cells, 71% had obvious ascites, 86% had CA-125 over the upper limit of reference, and 90% had ECOG (Eastern Cooperative Oncology Group) performance status greater than 1. The gene discussed is MUC16; the disease is neoplasm.